Identifying familial hypercholesterolemia in acute coronary syndrome

Current Opinion in Lipidology

Volumn 27, Issue 4, 2016, Pages 375-381

  Gencer, Baris ^a   Nanchen, David ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

acute coronary syndrome; cardiovascular prevention; familial hypercholesterolemia; lipids; proprotein convertase subtilisin kexin type 9

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 INHIBITOR; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH CARE QUALITY; HEART REHABILITATION; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; META ANALYSIS (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; ANTAGONISTS AND INHIBITORS; COMPLICATION;

ACUTE CORONARY SYNDROME; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PREVALENCE; PROGNOSIS; PROPROTEIN CONVERTASE 9; QUALITY OF HEALTH CARE;

EID: 84964378012     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000311     Document Type: Review

References (46)

1. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490a.
2. Wiegman A, Gidding SS, Watts GF, et al. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 2015; 36:2425-2437.
3. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012; 97:3956-3964.
4. Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J CardiolS 2011; 108:223-226.
5. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: A long term cohort study. BMJ 2008; 337:a2423.
6. Hovingh GK, Davidson MH, Kastelein JJ, O'Connor AM. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013; 34:962-971.
7. Foody JM. Familial hypercholesterolemia: An under-recognized but significant concern in cardiology practice. Clin Cardiol 2014; 37:119-125.
8. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur Heart J 2008; 29:2625-2633.
9. Nanchen D, Gencer B, Auer R, et al. Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. Eur Heart J 2015; 36:2438-2445.
10. European Association for Cardiovascular Prevention & Rehabilitation. Catapano AL, De Backer G, Reiner Z, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
11. Hopkins PN, Toth PP, Ballantyne CM, et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S9-17.
12. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014; 171:309-325.
13. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303:893-896.
14. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. BMJ 2008; 337:a1095.
15. Gidding SS, Ann Champagne M, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: A scientific statement from the American Heart Association. Circulation 2015; 132:2167-2192
16. Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study. Lancet 2013; 381:1293-1301.
17. Wald DS, Bangash FA, Bestwick JP. Prevalence of DNA-confirmed familial hypercholesterolaemia in young patients with myocardial infarction. Eur J Int Med 2015; 26:127-130.
18. Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol 2008; 102:1187-1193.
19. De Backer G, Besseling J, Chapman J, et al. Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. Atherosclerosis 2015; 241:169-175
20. Pang J, Poulter EB, Bell DA, et al. Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. Journal of clinical lipidology 2015; 9:703-708.
21. Yudi M, Omera L, McCubbery N, et al. Suboptimal consideration and management of potential familial hypercholesterolaemia in patients with suspected premature coronary artery disease. Singapore Med J 2012; 53:174-178.
22. Gencer B, Montecucco F, Nanchen D, et al. Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J 2016; 37:546-553.
23. Lim GB. Acute coronary syndromes: low prognostic utility of measuring PCSK9 levels in ACS. Nature reviews. Cardiology 2016; 13:62-63.
24. Selby K, Nanchen D, Auer R, et al. Low statin use in adults hospitalized with acute coronary syndrome. Preventive Med 2015; 77:131-136.
25. Stone NJ, Robinson JG, LichtensteinAH, et al. 2013ACC/AHAguideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1-S45.
26. Fulcher J, O'Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174000 participants in 27 randomised trials. Lancet 2015; 385:1397-1405.
27. Auer R, Gencer B, Raber L, et al. Quality of care after acute coronary syndromes in a prospective cohort with reasons for nonprescription of recommended medications. PloS One 2014; 9:e93147.
28. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36:1012-1022.
29. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: A cohort study. Ann Int Med 2013; 158:526-534.
30. Gencer B, Rodondi N, Auer R, et al. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. Eur J Int Med 2015; 26:56-62.
31. Gencer B, Auer R, Nanchen D, et al. Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis 2015; 239:118-124.
32. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation: Task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37:267-315.
33. Scientific Steering Committee on behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142:105-112.
34. Besseling J, Kindt I, Hof M, et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14 000 mutation carriers. Atherosclerosis 2014; 233:219-223.
35. Huijgen R, Kindt I, Defesche JC, Kastelein JJ. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: A study among 29 365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants. Eur Heart J 2012; 33:2325-2330.
36. Mohrschladt MF, Westendorp RG, Gevers Leuven JA, Smelt AH. Cardiovascular disease and mortality in statin-treated patients with familial hypercholesterolemia. Atherosclerosis 2004; 172:329-335.
37. Gencer B, Lambert G, Mach F. PCSK9 inhibitors. Swiss Med Wkly 2015; 145:w14094.
38. Gencer B, Laaksonen R, Buhayer A, Mach F. Use and role of monoclonal antibodies and other biologics in preventive cardiology. Swiss Med Wkly 2015; 145:w14179.
39. Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 Inhibitors: The clinical benefit of lipid drugs. New Engl J Med 2015; 373:1588-1591.
40. Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1: full report. Journal Clinical Lipidol 2015; 9:129-169.
41. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis. Ann Int Med 2015; 163:40-51.
42. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500-1509.
43. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. New Engl J Med 2015; 372:1489-1499.
44. Gencer B, Mach F. Sweetless'n low LDL-C targets for PCSK9 treatment. Eur Heart J 2015; 36:1146-1148.
45. Santos RD, Watts GF. Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet 2015; 385:307-310.
46. Tice JA, Kazi DS, Pearson SD. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value. JAMA Int Med 2016; 176:107-108.